38.9 F
New York
Sunday, January 17, 2021

Here’s the Scoop on Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

Must read

American Battery Metals Corp (OTCMKTS:ABML) Hitting Key Milestones

Over the course of the past week, American Battery Metals Corp (OTCMKTS:ABML) has been in focus among investors after the company announced...

American Green Inc (OTCMKTS:ERBB) Stock Gains Momentum on Amazon News

One of the more interesting operators in the cannabis space in 2020 is American Green Inc (OTCMKTS:ERBB), and this week, the company...

DSG Global Inc (OTCMKTS:DSGT) Hits Multi-Month High On Sudden Optimism

DSG Global Inc (OTCMKTS:DSGT) has been in the news over the past week or so after the company placed large orders through...

AppYea Inc (OTCMKTS:APYP) Stock Gains Momentum on High Volume

Over the past couple of weeks, many stocks in the over-the-counter market have recorded considerable gains and one of the notable ones...

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017.

When a company needs cash it is bad for common shareholders. This dilution always comes out in the share price, and the price action in Northwest Biotherapeutics is expected and predictable. A look at any 1 year chart (see below) shows the path as clear as day, the stock was +30% for the year and once the dilution was processed investors scrambled sending shares down -30% for the year. The common stock holder is always the recipient of the negative price action when the company needs money. The banker is often viewed as the black hat in the movie, but they are performing a function needed by microcap players. Few understand the shark tank nature of investing and funding smaller companies in 2017 capital markets.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) sold to several institutional investors securities totaling 28,843,692 shares, comprised of 18,843,692 common shares at $.26 per share, and 10,000,000 shares of Class C Warrants pre-funded at the closing at $.25 cents per future exercisable shares, with a one cent per share additional payment to be made at the time of actual exercise of these warrants. This arrangement is to enable investors to avoid exceeding 4.99% ownership while still funding $7.5 million.

Additionally, the investors received five year Class A warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $0.26 per share.  They also will receive three month Class B warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $1.00 per share. These are the payoffs for the bankers for completing the deal and the final product for funding.

Find out when $NWBO stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

NWBO 1 year chart below.

A clinical hold on phase 3 trials for a brain cancer immunotherapy candidate from Northwest Biotherapeutics Inc. was recently lifted by the U.S. Food and Drug Administration which is the fundamental action driving all of the restructuring. The Bethesda-based company is working to develop products to stimulate the human immune system to reverse tumor growth and kill cancer cells and has several human clinical trials underway. The trial in question, DCVax-L, is for for glioblastoma multiforme brain cancer.

The company was 17 patients shy of its planned 348-patient trial when the FDA closed enrollment in 2015. Patients in the trial were allowed to continue being treated.

Despite the lifting of the hold, Northwest Bio said it doesn’t plan to reopen enrollment since it was able to accumulate a sufficient number of events toward measuring progression-free survival and expects to have enough data endpoints for overall survival within the next several months. The company has previously said it would not be “worth the time it would take” to restart enrollment.

It’s positive news for the company which has had a tumultuous couple of years. Most recently, the company voluntarily delisted its stock from the Nasdaq Capital Market in December. It came after the exchange notified the company that it no longer met requirements for listing. This is not that unusual really – many companies are notified by the exchanges to meet requirements, so it is not the death knell it seems, and for Northwest Biotherapeutics (OTCMKTS:NWBO) the shareholders feel like it is safe to go back in the water. For continuing coverage on shares of $NWBO stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!


Latest article

Ozop Energy Solutions Inc (OTCMKTS:OZSC) Remains Volatile: Stock in Focus

Those who are looking to discover stocks that may have made big moves over the course of the past week could consider...

Data Storage Corp (OTCMKTS:DTST) Gets Sudden Attention: What’s The Buzz?

One of the stocks to have made significant gains this week was that of Data Storage Corp (OTCMKTS:DTST). The Data Storage Corporation...

A Closer Looks at American Battery Metals Corp (OTCMKTS:ABML) Developments

American Battery Metals Corp (OTCMKTS:ABML) is one of the stocks to have been in focus among investors over the course of the...

Why is Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) In a Bearish Trend?

The Bitcoin rally over the past weeks has taken the crypto space by storm. However, it should not be forgotten that Ethereum,...

Curaleaf Holdings (OTCQX:CURLF) Continues to Hit New Highs: Next Move?

The cannabis sector has had its ups and downs over the last year, but there are certain stocks that are almost always...